Science Daily September 15, 2022
To evaluate the impact of mutations on 17 antibodies used in 11 commercially available antigen tests with emergency use authorization a team of researchers in the US (Emory University, Baylor College, industry) measured antibody binding for all possible Nucleocapsid point mutations using a mammalian surface-display platform and deep mutational scanning. The results provided a complete map of the antibodies’ epitopes and their susceptibility to mutational escape. Their data predicted no vulnerabilities for detection of mutations found in variants of concern. They confirmed this using the commercial tests and sequence-confirmed COVID-19 patient samples. The antibody escapes mutational profiles generated here serve as a valuable resource for predicting the performance of rapid antigen tests against past, current, as well as any possible future variants of SARS-CoV-2, establishing the direct clinical and public health utility of our system…read more. Open Access TECHNICAL ARTICLEÂ
Graphical abstract. Credit: Cell, VOLUME 185, ISSUE 19, P3603-3616.E13, SEPTEMBER 15, 2022Â